OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
OKYO Pharma (NASDAQ: OKYO) has been granted a key European Patent for its OK-101 chemerin analogs and their method of use. This patent, titled 'Compositions Comprising Chemerin Analogs and Methods of Use', strengthens OKYO's intellectual property position in treating ocular inflammatory and pain conditions.
The company is developing innovative therapies for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), which currently lacks FDA-approved treatments. Dr. Gary S. Jacob, CEO of OKYO, emphasized the patent's importance in advancing novel therapies for ocular pain and inflammation. The company is exploring strategic partnerships to accelerate the development and commercialization of its pipeline candidates.
OKYO Pharma (NASDAQ: OKYO) ha ricevuto un importante brevetto europeo per i suoi analoghi di chemerina OK-101 e il loro metodo di utilizzo. Questo brevetto, intitolato 'Composizioni Comprendenti Analoghi di Chemerina e Metodi di Utilizzo', rafforza la posizione di proprietà intellettuale di OKYO nel trattamento delle condizioni infiammatorie oculari e del dolore.
L'azienda sta sviluppando terapie innovative per la malattia da occhio secco infiammatorio (DED), un mercato da miliardi di dollari, e per il dolore corneale neuropatico (NCP), che attualmente non dispone di trattamenti approvati dalla FDA. Il Dr. Gary S. Jacob, CEO di OKYO, ha sottolineato l'importanza del brevetto per l'avanzamento di terapie innovative per il dolore e l'infiammazione oculari. L'azienda sta esplorando partnership strategiche per accelerare lo sviluppo e la commercializzazione dei suoi candidati pipeline.
OKYO Pharma (NASDAQ: OKYO) ha sido otorgada una patente europea clave para sus análogos de chemerina OK-101 y su método de uso. Esta patente, titulada 'Composiciones que Comprenden Análogos de Chemerina y Métodos de Uso', refuerza la posición de propiedad intelectual de OKYO en el tratamiento de condiciones inflamatorias oculares y de dolor.
La empresa está desarrollando terapias innovadoras para la enfermedad del ojo seco inflamatorio (DED), un mercado de miles de millones de dólares, y para el dolor corneal neuropático (NCP), que actualmente carece de tratamientos aprobados por la FDA. El Dr. Gary S. Jacob, CEO de OKYO, enfatizó la importancia de la patente en el avance de nuevas terapias para el dolor y la inflamación ocular. La empresa está explorando asociaciones estratégicas para acelerar el desarrollo y la comercialización de sus candidatos en investigación.
OKYO 제약 (NASDAQ: OKYO)은 OK-101 케머린 유사체 및 그 사용 방법에 대한 주요 유럽 특허를 부여받았습니다. 이 특허의 제목은 '케머린 유사체 및 사용 방법을 포함하는 조성물'이며, 이는 안구 염증 및 통증 치료에 있어 OKYO의 지적 재산권을 강화합니다.
회사는 수십억 달러 규모의 염증성 건성 안구 질환 (DED) 및 현재 FDA 승인 치료제가 없는 신경병리학적 각막 통증 (NCP)에 대한 혁신적인 치료법을 개발하고 있습니다. OKYO의 CEO인 Gary S. Jacob 박사는 이 특허가 안구 통증과 염증에 대한 새로운 치료법을 발전시키는 데 얼마나 중요한지를 강조했습니다. 회사는 파이프라인 후보의 개발 및 상용화를 가속화하기 위해 전략적 파트너십을 모색하고 있습니다.
OKYO Pharma (NASDAQ: OKYO) a obtenu un brevet européen clé pour ses analogues de chémérine OK-101 et leur méthode d'utilisation. Ce brevet, intitulé 'Compositions Comprenant des Analogues de Chémérine et Méthodes d'Utilisation', renforce la position de propriété intellectuelle d'OKYO dans le traitement des inflammations oculaires et de la douleur.
L'entreprise développe des thérapies innovantes pour la maladie de l'œil sec inflammatoire (DED), un marché de plusieurs milliards de dollars, et pour la douleure cornéenne neuropathique (NCP), qui ne dispose actuellement d'aucun traitement approuvé par la FDA. Le Dr Gary S. Jacob, PDG d'OKYO, a souligné l'importance de ce brevet pour faire avancer les nouvelles thérapies contre la douleur et l'inflammation oculaires. L'entreprise explore des partenariats stratégiques pour accélérer le développement et la commercialisation de ses candidats en développement.
OKYO Pharma (NASDAQ: OKYO) hat ein wichtiges europäisches Patent für seine OK-101-Chemerin-Analoga und deren Verwendungsmethode erhalten. Dieses Patent mit dem Titel 'Zusammensetzungen mit Chemerin-Analoga und Verwendungsmethoden' stärkt die geistigen Eigentumsrechte von OKYO zur Behandlung von Augenentzündung und Schmerz.
Das Unternehmen entwickelt innovative Therapien für entzündliche trockene Augenkrankheit (DED), einen Markt im Milliardenbereich, und neuropathischen Hornhautschmerz (NCP), für den es derzeit keine von der FDA zugelassenen Behandlungen gibt. Dr. Gary S. Jacob, CEO von OKYO, betonte die Bedeutung des Patents für den Fortschritt neuer Therapien bei Augenbeschwerden und Entzündungen. Das Unternehmen prüft strategische Partnerschaften, um die Entwicklung und Vermarktung seiner Pipeline-Kandidaten zu beschleunigen.
- Granted a key European Patent for OK-101 chemerin analogs and their method of use
- Strengthens intellectual property position in treating ocular inflammatory and pain conditions
- Developing therapies for inflammatory dry eye disease (DED), a multi-billion-dollar market
- Exploring strategic partnerships to accelerate development and commercialization
- None.
This patent grant significantly bolsters OKYO Pharma's intellectual property portfolio in Europe. The broad scope covering "chemerin analogs and their method of use" provides strong market exclusivity for OK-101 and related compounds. This protection is important for:
- Deterring potential competitors
- Attracting partnerships and licensing deals
- Increasing the company's valuation
However, it's important to note that while patent protection is valuable, it doesn't guarantee commercial success. The company still needs to demonstrate clinical efficacy and obtain regulatory approvals. The 20-year patent term from the filing date also means OKYO must move quickly to maximize the commercial potential within this window.
The patent's focus on ocular inflammatory and pain conditions is particularly intriguing. Dry Eye Disease (DED) affects millions globally, with current treatments often providing inadequate relief. More importantly, Neuropathic Corneal Pain (NCP) lacks FDA-approved therapies, representing a significant unmet need. OK-101's potential to address both conditions could be groundbreaking. However, it's important to temper excitement with caution:
- Clinical trials must still prove efficacy and safety
- Regulatory hurdles remain before market approval
- Patient adoption and physician acceptance are yet to be determined
If successful, OK-101 could dramatically improve quality of life for patients suffering from these debilitating ocular conditions.
This patent grant strengthens OKYO Pharma's position in the competitive ophthalmology market. Key points to consider:
- The multi-billion-dollar DED market presents a substantial opportunity
- Being first-to-market for NCP could provide a significant advantage
- The company's focus on "strategic partnerships and collaborations" suggests potential for future deals
However, investors should note that OKYO is still in the clinical stage, with no approved products or revenue. The path to commercialization is long and risky. While this patent is a positive step, it's just one piece of the puzzle. Financial runway, clinical trial results and regulatory outcomes will be critical factors in determining OKYO's long-term success and stock performance.
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: “Compositions Comprising Chemerin Analogs and Methods of Use”. The present disclosure that lists Raj Patil, Chief Scientific Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and conditions including but not limited to, ocular inflammatory and pain conditions, strengthening the Company’s intellectual property position in this field.
"We are delighted with the issuance of this European patent, which underscores the innovative nature of our OK-101 chemerin analogs and their therapeutic potential. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates.”
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What patent did OKYO Pharma (NASDAQ: OKYO) recently receive in Europe?
What are the main therapeutic areas OKYO Pharma (NASDAQ: OKYO) is focusing on?
How does the new European patent benefit OKYO Pharma (NASDAQ: OKYO)?
What is OKYO Pharma's (NASDAQ: OKYO) strategy for advancing its pipeline candidates?
